Thelansis

Prostate Cancer Market Outlook Thelansis’s “Prostate Cancer Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Prostate Cancer treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Prostate Cancer Overview Prostate cancer is the most common malignancy in men, arising from prostatic glandular epithelium driven by androgen receptor signalling, with somatic alterations in PTEN, TP53, RB1, and DNA repair genes including BRCA1, BRCA2, and CDK12 underpinning aggressive and castration-resistant disease biology. Patients present with urinary symptoms, elevated PSA, or incidentally detected nodules, with many diagnosed through PSA-based scr...

Prostate Cancer Market Outlook Thelansis’s “Prostate Cancer Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Prostate Cancer treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Prostate Cancer Overview Prostate cancer is the most common malignancy in men, arising from prostatic glandular epithelium driven by androgen receptor signalling, with somatic alterations in PTEN, TP53, RB1, and DNA repair genes including BRCA1, BRCA2, and CDK12 underpinning aggressive and castration-resistant disease biology. Patients present with urinary symptoms, elevated PSA, or incidentally detected nodules, with many diagnosed through PSA-based scr...

Prostate Cancer Market Outlook Thelansis’s “Prostate Cancer Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Prostate Cancer treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China) . Key business questions answered: How  can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and patient share? Which events will have the greatest impact on the market’s trajectory? What...

Prostate Cancer Market Outlook Thelansis’s “Prostate Cancer Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Prostate Cancer treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Key business questions answered: How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and patient share? Which events will have the greatest impact on the market’s trajectory? What insights do...

 Prostate cancer, characterized by its lengthy disease trajectory and diverse clinical outcomes among individual patients, predominantly affects men aged 45 to 60. Risk factors associated with this cancer encompass familial predisposition, ethnicity, age, obesity, and various environmental influences, with familial inheritance being a significant genetic risk factor. The majority of newly diagnosed prostate cancer cases initially present with localized disease, typically managed through radical prostatectomy and radiation therapy, followed by androgen deprivation therapy (ADT). However, within a decade, a variable percentage of patients progress to castration-resistant prostate cancer (CRPC). Among them, those with metastatic castration-resistant prostate cancer (MCRPC) face a particularly grim prognosis, with median survival ranging from 9 to 30 months for CRPC and reduced to 9–13 months for MCRPC. Current therapeutic strategies for MCRPC include cytotoxic chemotherapy agents, and...

  Prostate cancer (PCa) is one of the most prevalent malignancies globally. Most men with newly diagnosed PCa present with localized disease and undergo radical prostatectomy and radiological therapy, followed by androgen deprivation therapy (ADT). Depending on the cancer grade, a variable percentage of these patients experience castration-resistant prostate cancer (CRPC) progression within ten years. Metastatic castration-resistant prostate cancer (MCRPC) patients remain incurable, and the prognosis of these patients is relatively poor. For men with CRPC, the median survival ranges from 9 to 30 months, and for those with MCRPC, this survival is reduced to 9–13 months. Currently, cytotoxic chemotherapy agents, AR blocking agents, immunotherapies, and radiopharmaceuticals represent effective therapeutic strategies for MCRPC treatment. Taxane chemotherapy (docetaxel and cabazitaxel) is the standard for MCRPC treatment. The incidence of cases of Prostate cancer (PCa) ranges f...